BRIEF-Asterias biotherapeutics receives safety clearance to begin administering the highest dose of AST-OPC1 in the SCiStar phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients

* Asterias Biotherapeutics receives safety clearance to
begin administering the highest dose of AST-OPC1 in the SCiStar
Phase 1/2a clinical trial in cervical spinal cord injury
patients

The post BRIEF-Asterias biotherapeutics receives safety clearance to begin administering the highest dose of AST-OPC1 in the SCiStar phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients appeared first on NASDAQ.